Popular Blood Pressure Medicine May Do More Harm Than Good
WebMD News Archive
Aug. 29, 2000 (Amsterdam) -- A highly popular but expensive type of blood pressure medication may be responsible for an excessive number of heart attacks and cases of heart failure. Although the drugs, known as long-acting calcium channel blockers, effectively lower blood pressure as well as less expensive alternatives, a new study shows that they do not prevent the cardiovascular complications of high blood pressure.
Use of any of the long-acting calcium channel blockers leads to about 40,000 "unnecessary or excess" heart attacks in the U.S. each year and about 85,000 "excess events" worldwide, Marco Pahor, MD, tells WebMD. Pahor, a professor of medicine at Wake Forest University School of Medicine in Winston-Salem, N.C., headed the team of researchers who wrote the new study.
There are several different brands of these drugs on the market, but among the better known are Procardia XL, Norvasc, Cardizem CD, and Adalat CC. The annual cost of high blood pressure treatment with these drugs, which are taken daily, ranges from $740 to $990 a year. That, says Pahor, is much more expensive than treatment with another kind of drug called a diuretic that can cost only about $60 a year.
One of the reasons for the big difference in cost is that long-acting calcium channel blockers are only available as brand-name drugs, while the other, more effective blood pressure drugs -- diuretics, beta-blockers, and ACE inhibitors -- are available in generic formulations, says Pahor.
The researchers analyzed data from nine studies that compared the outcomes of patients taking a calcium channel blocker to the outcomes of patients treated with other drugs to treat high blood pressure. All 27,743 patients included in the nine studies had high blood pressure (also called hypertension), meaning a blood pressure of more than 140/90.
They found that people taking long-acting calcium channel blockers had a "27% higher risk of heart attack and 26% higher risk of congestive heart failure than did persons taking diuretics, beta-blockers, or ACE inhibitors," Pahor says.
The findings were presented Tuesday at an international cardiology meeting in Amsterdam, the Netherlands, by Pahor's colleague, Curt D. Furberg, MD, PhD, who is a professor of public health at Wake Forest University School of Medicine.